Vonicog alfa - Wikipedia
Vonicog alfa, sold under the brand names Vonvendi and Veyvondi, is a medication used to control bleeding in adults with von Willebrand disease (an inherited bleeding disorder). [6] [5] [7] [8] It …
Veyvondi | European Medicines Agency (EMA)
Veyvondi is a medicine used to control bleeding in adults with von Willebrand disease (an inherited bleeding disorder) who cannot be treated with desmopressin (another medicine to …
VEYVONDI should be administered with recombinant factor VIII if the FVIII:C levels are < 40%, or are unknown, to control bleeding. The rFVIII dose should be calculated according to the …
VEYVONDI is used to prevent and treat bleeding episodes, including bleeding during surgery in adult patients (aged 18 years and older) with von Willebrand disease. It is used when …
Veyvondi is a medicine used to control bleeding in adults with von Willebrand disease (an inherited bleeding disorder) who cannot be treated with desmopressin (another medicine to …
VEYVONDI 650 IU powder and solvent for solution for injection
VEYVONDI is a recombinant human von Willebrand factor (rVWF). VEYVONDI behaves in the same way as endogenous von Willebrand factor. Administration of VEYVONDI allows …
欧洲首个治疗血管性血友病（VWD）的重组VWF药物Veyvondi即 …
2018年7月6日 · 如果获批，Veyvondi将成为欧洲首个也是唯一一个治疗VWD的rVWF药物，专门解决VWF的原发性缺陷或功能障碍，同时使身体恢复或维持足够的因子VIII（FVIII）血浆水平。
夏尔止血药物 Veyvondi 获欧盟批准 - 丁香园
2018年9月18日 · PMLiVE 于 9 月 13 日报道，欧盟委员会批准夏尔（Shire）止血药物 Veyvondi，其旨在血管性血友病（VWD）成人患者中用于预防手术出血。 该药物以注射剂使 …
EMA 受理 Shire 血管性血友病药物 Veyvondi 上市申请 - 丁香园
2017年6月29日 · Veyvondi 是一种 VWF 替代疗法，其不添加任何人类或动物来源的外源性原料，所以这款产品只含有微量的 FVIII。「从临床特征及生理学来说，Veyvondi 是该类血管性血 …
Vonvendi（重组血管性血友病因子）中文说明书 - 价格 - 功效及副 …
Vonvendi（血管假性血友病因子 [重组体]）用于18岁及以上年龄的血管性血友病患者。 Vonvendi 是首款获FDA批准的重组血管假性血友病因子，在确诊患有血管性血友病的成年患者中，该药 …
- 某些结果已被删除